Literature DB >> 20739403

DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

Kyung Song1, Hui Wang, Tracy L Krebs, Bingcheng Wang, Thomas J Kelley, David Danielpour.   

Abstract

Androgens suppress TGF-β responses in the prostate through mechanisms that are not fully explored. We have recently reported that 5α-dihydrotestosterone (DHT) suppresses the ability of TGF-β to inhibit proliferation and induce apoptosis of prostatic epithelial cells and provided evidence that such suppression was fueled by transcriptional down-regulation of TGF-β receptor II (ΤβRII). We now show that androgen receptor (AR) activated by DHT suppresses the TGF-β-induced phosphorylation of Sma- and Mad-related protein (Smad)3 in LNCaP cells overexpressing TβRII under the control of a cytomegalovirus promoter, which is not regulated by DHT, suggesting that transcriptional repression of TβRII alone does not fully account for the impact of DHT on TGF-β responses. Instead, we demonstrate that such suppression occurs through loss of total Smad3, resulting from transcriptional suppression of Smad3. We provide evidence that DHT down-regulates the promoter activity of Smad3 in various prostate cancer cell lines, including NRP-154+AR, DU145+AR, LNCaP, and VCaP, at least partly through androgen-dependent inactivation of Sp1. Moreover, we show that overexpression of Smad3 reverses the ability of DHT to protect against TGF-β-induced apoptosis in NRP-154+AR, supporting our model that loss of Smad3 by DHT is involved in the protection against TGF-β-induced apoptosis. Together, these findings suggest that deregulated/enhanced expression and activation of AR in prostate carcinomas may intercept the tumor suppressor function of TGF-β through transcriptional suppression of Smad3, thereby providing new mechanistic insight into the development of castration-resistant prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739403      PMCID: PMC2954637          DOI: 10.1210/me.2010-0165

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  51 in total

Review 1.  Androgen receptor corepressors and prostate cancer.

Authors:  Craig J Burd; Lisa M Morey; Karen E Knudsen
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

2.  Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Seong-Jin Kim; David Danielpour
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 3.  Targeting the androgen receptor pathway in prostate cancer.

Authors:  Yu Chen; Charles L Sawyers; Howard I Scher
Journal:  Curr Opin Pharmacol       Date:  2008-08-12       Impact factor: 5.547

4.  Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement.

Authors:  H F English; R J Santen; J T Isaacs
Journal:  Prostate       Date:  1987       Impact factor: 4.104

5.  Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55.

Authors:  H Wang; K Song; T L Krebs; J Yang; D Danielpour
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

6.  mTOR cascade activation distinguishes tubers from focal cortical dysplasia.

Authors:  Marianna Baybis; Jia Yu; Allana Lee; Jeff A Golden; Howard Weiner; Guy McKhann; Eleonora Aronica; Peter B Crino
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

7.  Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression.

Authors:  J Yang; K Song; T L Krebs; M W Jackson; D Danielpour
Journal:  Oncogene       Date:  2008-05-26       Impact factor: 9.867

8.  Transcriptional regulation of the TGF-beta1 promoter by androgen receptor.

Authors:  Wei Qi; Shen Gao; Zhengxin Wang
Journal:  Biochem J       Date:  2008-12-15       Impact factor: 3.857

9.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.

Authors:  Veronica R Placencio; Ali-Reza Sharif-Afshar; Xiaohong Li; Hongxia Huang; Consolate Uwamariya; Eric G Neilson; Michael M Shen; Robert J Matusik; Simon W Hayward; Neil A Bhowmick
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells.

Authors:  Jenny Y Lee; Heather L Elmer; Kristie R Ross; Thomas J Kelley
Journal:  Am J Respir Cell Mol Biol       Date:  2004-03-25       Impact factor: 6.914

View more
  20 in total

1.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

Review 2.  Interrogating genomic and epigenomic data to understand prostate cancer.

Authors:  Jung Kim; Jindan Yu
Journal:  Biochim Biophys Acta       Date:  2012-01-03

3.  P21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition.

Authors:  Ahmad Al-Azayzih; Fei Gao; Payaningal R Somanath
Journal:  Biochim Biophys Acta       Date:  2015-03-06

4.  Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanism.

Authors:  Wannarasmi Ketchart; I-Ju Yeh; Haoyan Zhou; Praveena S Thiagarajan; Justin Lathia; Ofer Reizes; Agata Exner; Bin Su; Monica M Montano
Journal:  Cancer Lett       Date:  2016-05-26       Impact factor: 8.679

5.  Cooperation between Polycomb and androgen receptor during oncogenic transformation.

Authors:  Jonathan C Zhao; Jianjun Yu; Christine Runkle; Longtao Wu; Ming Hu; Dayong Wu; Jun S Liu; Qianben Wang; Zhaohui S Qin; Jindan Yu
Journal:  Genome Res       Date:  2011-12-16       Impact factor: 9.043

6.  Predominant suppression of follicle-stimulating hormone β-immunoreactivity after long-term treatment of intact and castrate adult male rats with the gonadotrophin-releasing hormone agonist deslorelin.

Authors:  A W Smith; C S Asa; B S Edwards; W J Murdoch; D C Skinner
Journal:  J Neuroendocrinol       Date:  2012-05       Impact factor: 3.627

7.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

8.  Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.

Authors:  Tzu-Hua Lin; Soo Ok Lee; Yuanjie Niu; Defeng Xu; Liang Liang; Lei Li; Shauh-Der Yeh; Naohiro Fujimoto; Shuyuan Yeh; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

9.  Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer.

Authors:  Ken-Ichi Takayama; Kuniko Horie-Inoue; Shintaro Katayama; Takashi Suzuki; Shuichi Tsutsumi; Kazuhiro Ikeda; Tomohiko Urano; Tetsuya Fujimura; Kiyoshi Takagi; Satoru Takahashi; Yukio Homma; Yasuyoshi Ouchi; Hiroyuki Aburatani; Yoshihide Hayashizaki; Satoshi Inoue
Journal:  EMBO J       Date:  2013-05-03       Impact factor: 11.598

10.  Critical role of a survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells.

Authors:  Kyung Song; Eswar Shankar; Jiayi Yang; Kara L Bane; Reema Wahdan-Alaswad; David Danielpour
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.